Literature DB >> 17083765

A proposed approach to recognise "near-remission" quantitatively without formal joint counts or laboratory tests: a patient self-report questionnaire routine assessment of patient index data (RAPID) score as a guide to a "continuous quality improvement" s.

T Pincus1, Y Yazici, M Bergman, C Swearingen, T Harrington.   

Abstract

A proposed approach is presented to recognise a status of "near-remission" in a patient with rheumatoid arthritis (RA) on the basis of patient self-report questionnaire data without formal joint counts or laboratory tests. Indices of patient-reported outcome (PRO) measures distinguish active from control treatments in RA clinical trials at levels similar to American College of Rheumatology (ACR) or disease activity score (DAS) 28 improvement levels. PRO measures on a multidimensional health assessment questionnaire (MDHAQ) can be compiled into a routine assessment of patient index data (RAPID) score. RAPID 3 includes the three PRO measures from the ACR Core Data Set - physical function, pain, and global estimate. RAPID 4 adds a self-report joint count from a rheumatoid arthritis disease activity index (RADAI). RAPID 5 adds a physician estimate of global status. RAPID cores may be classified into four preliminary proposed categories, as "near-remission" (0-1), "low severity" (1.01-2), "moderate severity" (2.01-4), and "high severity" (> 4), analogous to the four categories of the DAS28 of "remission" (< 2.6), as well as "low" (2.6-3.19), "moderate" (3.2-5.1), and "high" (> 5.1) disease activity. RAPID scores are correlated significantly with DAS28 (rho = 0.64-0.67, p < 0.001), and about 75% of patients with DAS < 2.6 have RAPID scores < 2, while about 75% of patients with DAS > 5.1 have RAPID scores > 4. RAPID data are available on one side of one page, and are feasible to collect in standard clinical care. RAPID 3 scores may be calculated in about 10 seconds, and RAPID 4 and RAPID 5 scores in 20 to 30 seconds. RAPID scores every 3 months or more on simple flowsheets can be a basis for a "continuous quality improvement" strategy in standard clinical care to recognise a need for aggressive therapy, an inadequate response to a therapy, and "near- remission" status.

Entities:  

Mesh:

Year:  2006        PMID: 17083765

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  7 in total

1.  Effects of long-term corticosteroid usage on functional disability in patients with early rheumatoid arthritis, regardless of controlled disease activity.

Authors:  Eiichi Tanaka; Ajitha Mannalithara; Eisuke Inoue; Noriko Iikuni; Atsuo Taniguchi; Shigeki Momohara; Gurkirpal Singh; Hisashi Yamanaka
Journal:  Rheumatol Int       Date:  2010-12-16       Impact factor: 2.631

2.  DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study.

Authors:  Michael Di Iorio; Claire E Cook; Kathleen M M Vanni; Naomi J Patel; Kristin M D'Silva; Xiaoqing Fu; Jiaqi Wang; Lauren C Prisco; Emily Kowalski; Alessandra Zaccardelli; Lily W Martin; Grace Qian; Tiffany Y-T Hsu; Zachary S Wallace; Jeffrey A Sparks
Journal:  Semin Arthritis Rheum       Date:  2022-05-18       Impact factor: 5.431

3.  DMARD disruption, disease flare, and prolonged symptom duration after acute COVID-19 among participants with rheumatic disease: A prospective study.

Authors:  Michael Di Iorio; Claire E Cook; Kathleen M M Vanni; Naomi J Patel; Kristin M D'Silva; Xiaoqing Fu; Jiaqi Wang; Lauren C Prisco; Emily Kowalski; Alessandra Zaccardelli; Lily W Martin; Grace Qian; Tiffany Y-T Hsu; Zachary S Wallace; Jeffrey A Sparks
Journal:  medRxiv       Date:  2022-02-09

Review 4.  Outcome measures in inflammatory rheumatic diseases.

Authors:  Jaap Fransen; Piet L C M van Riel
Journal:  Arthritis Res Ther       Date:  2009-10-14       Impact factor: 5.156

5.  Usefulness of patients-reported outcomes in rheumatoid arthritis focus group.

Authors:  Jenny Amaya-Amaya; Diana Botello-Corzo; Omar-Javier Calixto; Rolando Calderón-Rojas; Aura-Maria Domínguez; Paola Cruz-Tapias; Gladis Montoya-Ortiz; Ruben-Dario Mantilla; Juan-Manuel Anaya; Adriana Rojas-Villarraga
Journal:  Arthritis       Date:  2012-09-28

6.  Tools for monitoring remission in rheumatoid arthritis: any will do, let's just pick one and start measuring.

Authors:  Yusuf Yazici; Ismail Simsek
Journal:  Arthritis Res Ther       Date:  2013-01-28       Impact factor: 5.156

7.  Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia.

Authors:  Yvonne C Lee; James Hackett; Michelle Frits; Christine K Iannaccone; Nancy A Shadick; Michael E Weinblatt; Oscar G Segurado; Eric H Sasso
Journal:  Rheumatology (Oxford)       Date:  2015-11-25       Impact factor: 7.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.